Scinai Immunotherapeutics Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Stock price today
Loading chart…
Third-party market data · may be delayed
Model estimate per share
Not valued: the figures our models need are missing or failed our data-quality checks.
Price vs value
No model value: limited reported history: available models are shown without a Buy/Hold/Sell rating. How we value companies.
Scinai Immunotherapeutics Ltd. valuation: adjust assumptions and compare models →
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 287% in the quarter to 2023-12-31.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Scinai Immunotherapeutics Ltd.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 136% and a beta of 1.9 against the S&P 500.
- Heavily shorted. 13.5% of the shares available to trade are sold short (0.1 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.
Latest results
- Earnings per share
- -$240.00 against an average estimate of -$62.00: missed by 287.1%
Price chart
- 1 day+0.4%
- 1 week-12.5%
- 1 month-64.4%
- This year-93.3%
- 1 year-96.6%
- 5 years-100.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for SCNI from the sources we follow. See filings →
Valuation models
We value Scinai Immunotherapeutics Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.1 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Scinai Immunotherapeutics Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Scinai Immunotherapeutics Ltd.: too few analysts cover it.
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Dec 2023 | −$62.00 | −$240.00 | −287.1% |
| Sept 2023 | −$94.00 | $80.00 | +185.1% |
| Jun 2023 | −$91.00 | −$120.00 | −31.9% |
| Mar 2023 | −$73.00 | −$120.00 | −64.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 13.5% of tradable shares
- Days to cover
- 0.05 at average volume
- Short interest, 1 month
- −60% to October 15, 2026
- Held by institutions
- 1% of shares
- Held by insiders
- 2.7% of shares
- Employees
- 45 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| SCNI | −16% | −87% | −80% | −44% | −79% | −93% |
| Industry peers (median) | −36% | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| SCNI | 25% | 42% | 17% | 33% | 33% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| SCNI | −75% | −88% | −81% | −56% | −83% | −96% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 3, 2015: 100% from July 13, 2020 to October 30, 2026. Getting back needed a 10826171% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $0.47 – $12.70
- From 52-week high
- −96.3%
- vs 50-day average
- −67.9%
- vs 200-day average
- −89.3%
- Volatility (1 year)
- 136%
- Beta vs S&P 500
- 1.94
Fundamentals
Who owns it
- Reported value
- $49,076
- Institutions reporting
- 10
- Shares held vs prior quarter
- ▲ 603.4%
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Citadel Advisors LLC | $15,726 | 62K | 32.0% | New |
| Armistice Capital, LLC | $9,079 | 36K | 18.5% | New |
| Virtu Financial LLC | $5,000 | 19K | 10.2% | New |
| Stonex Group Inc. | $4,563 | 13K | 9.3% | New |
| Xtx Topco Ltd | $4,235 | 17K | 8.6% | ▼ 30.3% |
| Rhumbline Advisers | $3,417 | 14K | 7.0% | ▲ 619.5% |
| Captrust Financial Advisors | $3,040 | 12K | 6.2% | New |
| HRT Financial LP | $3,000 | 12K | 6.1% | New |
| UBS Group AG | $1,001 | 4K | 2.0% | ▲ 330.4% |
| Morgan Stanley | $15 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Scinai Immunotherapeutics Ltd.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Recent SEC filings
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Scinai Immunotherapeutics Ltd. in brief
- What does Scinai Immunotherapeutics Ltd. do?
- Scinai Immunotherapeutics Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Scinai Immunotherapeutics Ltd.'s stock ticker?
- Scinai Immunotherapeutics Ltd. trades under the ticker SCNI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Scinai Immunotherapeutics Ltd.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Citadel Advisors LLC, Armistice Capital, LLC and Virtu Financial LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Follow research on Scinai Immunotherapeutics Ltd.
New research on the companies we cover arrives in the weekly email. Free, one email a week.